ArticleOncology letters2025
Role and molecular mechanisms of hypoxia-derived exosomal miR-301a on gemcitabine resistance in pancreatic cancer.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Oncometabolites and Hypoxia-Regulated Exosomes Shape HIF-Driven Macrophage Programs Across Type 2 Diabetes, Atherosclerosis, and Cancer.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is a highly aggressive digestive malignancy and gemcitabine (GEM)-based chemotherapy remains a cornerstone of its treatment despite widespread resistance. The present study employed human pancreatic cancer cell lines to construct a hypoxia model, exosomes were isolated and characterized via ultracentrifugation, microRNA (miR)-301a expression was detected using reverse transcription-quantitative PCR, GEM resistance was evaluated via the Cell Counting Kit-8 assay and the molecular mechanisms were validated by western blotting. The present study results demonstrated that under hypoxic stress, pancreatic cancer cells displayed morphological adaptations typical of cellular stress responses, upregulated miR-301a expression and markedly enhanced GEM resistance. Hypoxia increases the number of exosomes, which can transfer miR-301a to normoxic pancreatic cancer cells. Under normoxic conditions, inhibiting miR-301a expression markedly increased the sensitivity of pancreatic cancer cells to GEM. Furthermore, miR-301a promoted the development of drug resistance by regulating acyl-CoA synthetase long-chain family member 4 (ACSL4) expression. In conclusion, the present study revealed a novel mechanism by which hypoxia-derived exosomal miR-301a promotes GEM resistance in pancreatic cancer by regulating ACSL4. These findings provide a novel potential target to reverse GEM resistance, with theoretical and practical implications for future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.